MX2022011291A - Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas. - Google Patents

Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas.

Info

Publication number
MX2022011291A
MX2022011291A MX2022011291A MX2022011291A MX2022011291A MX 2022011291 A MX2022011291 A MX 2022011291A MX 2022011291 A MX2022011291 A MX 2022011291A MX 2022011291 A MX2022011291 A MX 2022011291A MX 2022011291 A MX2022011291 A MX 2022011291A
Authority
MX
Mexico
Prior art keywords
gram
treatment
new
bacterial infections
negative bacterial
Prior art date
Application number
MX2022011291A
Other languages
English (en)
Spanish (es)
Inventor
Martínez Roberto Díez
Areizaga María Morales
Original Assignee
Telum Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telum Therapeutics S L filed Critical Telum Therapeutics S L
Publication of MX2022011291A publication Critical patent/MX2022011291A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01028—N-Acetylmuramoyl-L-alanine amidase (3.5.1.28)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022011291A 2020-03-11 2021-03-11 Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas. MX2022011291A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382177 2020-03-11
EP20382254 2020-03-31
PCT/EP2021/056264 WO2021180892A1 (en) 2020-03-11 2021-03-11 New recombinant lysin and its use in the treatment of gram-negative bacterial infections

Publications (1)

Publication Number Publication Date
MX2022011291A true MX2022011291A (es) 2022-12-08

Family

ID=74859480

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011291A MX2022011291A (es) 2020-03-11 2021-03-11 Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas.

Country Status (8)

Country Link
US (2) US12655409B2 (cg-RX-API-DMAC7.html)
EP (1) EP4118192A1 (cg-RX-API-DMAC7.html)
JP (2) JP7863509B2 (cg-RX-API-DMAC7.html)
CN (2) CN115605587B (cg-RX-API-DMAC7.html)
AU (1) AU2021236351A1 (cg-RX-API-DMAC7.html)
CA (1) CA3175024A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022011291A (cg-RX-API-DMAC7.html)
WO (1) WO2021180892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023139605A1 (en) * 2022-01-20 2023-07-27 Techinvention Lifecare Pvt. Ltd. Lysin polypeptides and compositions thereof against urinary tract infection caused by drug-resistant gram- negative bacteria
CN114774391B (zh) * 2022-03-09 2023-03-14 华南农业大学 一种抗大肠杆菌的噬菌体内溶素及其应用
WO2024231498A1 (en) * 2023-05-09 2024-11-14 BioNTech SE Intravaginal formulations of gardnerella endolysins
FR3149209B1 (fr) * 2023-06-02 2026-04-03 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique
WO2024246325A1 (en) * 2023-06-02 2024-12-05 L'oreal Cosmetic composition comprising an endolysin derived from a staphylococcus aureus phage and an aromatic alcohol
CN121420063A (zh) * 2023-06-30 2026-01-27 国立大学法人 冈山大学 可穿透革兰氏阴性菌外膜的多肽、包含所述多肽的抗菌蛋白、抗菌剂或消毒剂、药物组合物、以及抗菌剂组合物或消毒剂组合物
TW202541833A (zh) * 2023-12-12 2025-11-01 德商拜恩技術股份公司 包含內溶素之組合物及其用途
CN118420716B (zh) * 2024-05-28 2025-10-31 青岛农业大学 一种多肽125、包含多肽125的生物材料及应用
WO2026139534A1 (en) * 2024-12-24 2026-07-02 Telum Therapeutics, S.L. Antibacterial peptides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010002959A2 (en) * 2008-07-03 2010-01-07 The Rockefeller University A chimeric bacteriophage lysin with activity against staphylococci bacteria
PL2445515T3 (pl) 2009-06-26 2016-10-31 Środki przeciwdrobnoustrojowe
JP5847081B2 (ja) 2009-08-24 2016-01-20 カトリック ユニバーシテイト ルーベン ケイ.ユー. ルーベン アール アンド ディー エンドリシンOBPgpLYS
RU2614114C2 (ru) 2010-09-17 2017-03-22 Текнифар-Индустриа Текника Фармасьютика, С.А Бактериофаги, фаговые пептиды и способы их применения
GB201018518D0 (en) 2010-11-03 2010-12-15 Univ Leuven Kath Novel endolysin
EP2468856A1 (en) * 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
BR112016030580B1 (pt) 2014-06-26 2023-12-19 The Rockefeller University Polipeptídeo de lisina e fragmento de polipeptídeo com atividade para matar bactérias gram-negativas
ES2934714T3 (es) 2015-09-17 2023-02-24 Contrafect Corp Polipéptidos de lisina activos contra bacterias Gram-negativas
KR20240162610A (ko) * 2017-04-03 2024-11-15 사시나파스 컴퍼니 리미티드 조작된 그람-음성 엔도리신
CN111420037B (zh) * 2020-03-26 2022-05-10 中国农业科学院饲料研究所 噬菌体裂解酶Lysep3在制备广谱抗菌药物中的应用

Also Published As

Publication number Publication date
US20260226444A1 (en) 2026-08-06
JP2023517245A (ja) 2023-04-24
JP2026041893A (ja) 2026-03-10
US12655409B2 (en) 2026-06-16
WO2021180892A1 (en) 2021-09-16
CN115605587A (zh) 2023-01-13
CN115605587B (zh) 2026-02-13
JP7863509B2 (ja) 2026-05-21
AU2021236351A1 (en) 2022-10-06
US20230138922A1 (en) 2023-05-04
EP4118192A1 (en) 2023-01-18
CN121422198A (zh) 2026-01-30
CA3175024A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
PH12019500360A1 (en) Antibiotic compounds
Chessa et al. An overview of Staphylococcus epidermidis and Staphylococcus aureus with a focus on developing countries
JP2018509415A5 (cg-RX-API-DMAC7.html)
ZA202002093B (en) Antibacterial compounds
EP2046287A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING INFECTIONS
SA521430976B1 (ar) مضادات حيوية كبيرة الحلقة واسعة المدى
PH12019501904A1 (en) Macrocyclic broad spectrum antibiotics
WO2021247965A3 (en) Novel peptide inhibitors against beta-lactam resistance in bacteria
WO2021081110A3 (en) Peptides and use thereof
WO2020232471A3 (en) Methods and compositions comprising staphylococcus protein a (spa) variants
MXPA06000691A (es) Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables y uso de las mismas.
ATE510845T1 (de) Antibakterielle makrozyklen mit substituiertem biphenyl
Spanik et al. Viridans streptococcal bacteraemia due to penicillin-resistant and penicillin-sensitive streptococci: analysis of risk factors and outcome in 60 patients from a single cancer centre before and after penicillin is used for prophylaxis
AR073917A1 (es) Sinergismo antibiotico
WO2018140707A8 (en) Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces
TW200716162A (en) Use of bovine lactoferrin in the manufacture of a medicament for inhibiting the growth of bacteria
WO2005021575A3 (en) Bacterial signaling molecules that down-regulate pathogenic bacterial virulence properties
MX2023012943A (es) Compuesto antibacteriano.
EP4487917A3 (en) Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances
MX2021012375A (es) Metodo para tratar y prevenir infecciones oseas y de articulaciones.
Gaya et al. Comparative in vitro activity of cefuroxime and its interactions with aminoglycoside antibiotics
CL2025001925A1 (es) Polipéptido antimicrobiano micropacina k2, composición que lo comprende y uso para tratar infecciones bacterianas
Hashim et al. The role of antibiotic resistance mobile genetic element MCR-1 in enhancing bacterial survival in macrophages
WO2025186334A8 (en) Lipidic alkynylcarbinols with anti-bacterial and anti-tuberculosis activity
MX2019001280A (es) NUEVAS COMPOSICIONES FARMACEUTICAS CON UN PEPTIDO DE FUSION DE LA BETA-DEFENSINA MODIFICADA HßD3-M Y ANTIBIOTICOS COMERCIALES PARA SU USO EN EL TRATAMIENTO DE INFECCIONES CON BACTERIAS PATOGENAS.